Menu
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter.
1000 Winter St
Waltham, Massachusetts 02451-1436
Phone: 17818909989
www.neurometrix.com
https://www.investing.com/news/company-news/neurometrix-stock-plunges-to-52week-low-of-266-93CH-3569735
NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ETCompany ParticipantsThomas Higgins - Senior Vice President…
NeuroMetrix (NASDAQ: NURO ) just reported results for the second quarter of 2024. NeuroMetrix reported earnings per share of -74 cents. The company reported revenue of $769,148. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected]. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post NURO Stock Earnings: NeuroMetrix Reported Results for Q2 2024 appeared first on InvestorPlace .
